Atlas Trials

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Clinical trial NCT05639933 · RECRUITING

Trial details

NCT number
NCT05639933
Sponsor
Hoth Therapeutics, Inc.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Acneiform Eruption Due to ChemicalXerosis CutisParonychia
Start date
2023-07-19
Primary completion
2026-12-30
Enrollment
152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.